Physician profile
David E Stapp
NPI 1053343632
$8,292.70
in general payments reported to CMS, 2019-2025
38 companies · $1,636 in 2025
The $1,636 reported for 2025 was more than what 90% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $439 · 2020: $136 · 2021: $938 · 2022: $1,577 · 2023: $2,061 · 2024: $1,506 · 2025: $1,636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,102 · Education: $99.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,102.49 |
| Education | $99.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,757.17 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,614.36 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $646.97 | 2020-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $635.98 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $524.67 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $362.32 | 2021-2025 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $287.45 | 2021-2025 | Ocaliva |
| Abbvie INC. | $262.54 | 2021-2025 | Rinvoq, Skyrizi |
| Merck Sharp & Dohme LLC | $254.93 | 2019-2023 | Dificid |
| Celltrion USA INC. | $181.34 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Nestle Healthcare Nutrition INC. | $170.48 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $150.82 | 2023-2025 | Voquezna |
| Organon LLC | $117.01 | 2022-2025 | Renflexis, Hadlima |
| Novo Nordisk INC | $113.16 | 2023-2025 | Wegovy |
| Amgen INC. | $112.62 | 2022-2025 | Avsola, Amjevita, Uplizna |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $111.09 | 2024-2025 | Vowst, Zenpep |
| Shire North American Group INC | $89.44 | 2019 | |
| Pharmacosmos Therapeutics INC. | $81.38 | 2021-2024 | Monoferric |
| Tersera Therapeutics LLC | $80.67 | 2021-2023 | Xermelo, Zoladex |
| Csl Behring | $78.52 | 2019-2022 | |
| Daiichi Sankyo INC. | $66.27 | 2021-2023 | Injectafer |
| Madrigal Pharmaceuticals | $64.68 | 2025 | Rezdiffra |
| Celgene Corporation | $62.51 | 2022-2023 | Zeposia |
| Boston Scientific Corporation | $57.44 | 2022-2023 | Watchman Access System |
| Alnylam Pharmaceuticals INC. | $50.57 | 2021-2023 | Givlaari |
| Siemens Medical Solutions USA, INC. | $47.45 | 2023-2025 | Rapidpoint 400/405/500 Wash/Waste Cartridge, Rapidpoint 500e Blood Gas System |
| Fresenius Kabi USA, LLC | $46.90 | 2023-2024 | Idacio |
| Lilly USA, LLC | $45.28 | 2023-2024 | Omvoh |
| Evoke Pharma, INC. | $37.64 | 2021-2023 | Gimoti |
| Vivus LLC | $33.64 | 2021 | |
| Romark Laboratories, Lc | $25.34 | 2019 | |
| Ironwood Pharmaceuticals, INC | $24.94 | 2020 | |
| Sandoz INC. | $22.93 | 2023 | Hyrimoz |
| Astrazeneca Pharmaceuticals Lp | $18.98 | 2023 | Andexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.24 | 2023 | Cyltezo |
| Ipsen Biopharmaceuticals, INC | $14.63 | 2025 | Iqirvo |
| Shionogi INC | $12.44 | 2019 | |
| Ucb, INC. | $11.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Stapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.